Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-22
2008-11-18
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007910, C435S007920
Reexamination Certificate
active
07452678
ABSTRACT:
The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.
REFERENCES:
patent: 5279957 (1994-01-01), Gross
patent: 5817475 (1998-10-01), Gibbs et al.
patent: 6083763 (2000-07-01), Balch
patent: 6215894 (2001-04-01), Zeleny et al.
patent: 2003/0113708 (2003-06-01), Flint et al.
patent: 2004/0101874 (2004-05-01), Ghosh et al.
patent: WO2004030615 (2004-04-01), None
Adamus, et al., “Anti-Enolase-α Autoantibodies in Cancer-Associated Retinopathy: Epitope Mapping and Cytotoxicity on Retinal Cells”, J. Autoimmunity, vol. 11, pp. 671-677 (1998).
Al-Mulla, et al., “Raf Kinase Inhibitor Protein Expression in a Survival Analysis of Colorectal Cancer Patients”, J. Clin. Oncol., vol. 24, pp. 5672-5679 (2006).
Andrews, et al., “Exon Skipping in Purine Nucleoside Phosphorylase mRNA Processing Leading to Serve Immunodeficiency”, J. Biol. Chem., vol. 267(11), pp. 7834-7838 (1992).
Aust, et al., “Molecular Analysis of Mutations in a Patient with Purine Nucleoside Phosphorylase Deficiency”, Am. J. Hum. Genet., vol. 51, pp. 763-772 (1992).
Babia, et al., “Modulation of carcinoembryonic artigen release by glucosylceramide Implications for HT29 cell differentiation”, Eur. J. Biochem., vol. 258, pp. 233-242 (1998).
Barnidge, et al., “Extraction Method for Analysis of Detergent-Solubilized Bacetiorhodopsin and Hydrophobic Peptides by Electrospray Ionization Mass Spectrometry”, Anal. Biochem., vol. 269, pp. 1-9 (1999).
Bernhagen, et al., “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features”, J. Mol. Med., vol. 76, pp. 151-161 (1998).
Bernhage, et al., “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia”, Nature, vol. 365, pp. 756-759 (1993).
Borgers, et al., Purine Nucleoside Phosphorylase in Chronic Lymphocytic Leukemia (CLL), Blood, vol. 52(5), pp. 886-895 (1978).
Bourdi, et al., “Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stree responsiveness”, Biochem. Biophys. Res. Comm., vol. 294, pp. 225-230 (2002).
Brock, et al., “Co-localization of Leukotrience A4Hydrolase with 5-Lipoxygenase in Nuclei of Alveolar Maceophages and Rat Basophilic Leukemia Cells but Not Neutrophils”, J. Biol. Chem., vol. 276(37), pp. 35071-35077 (2001).
Calandra, et al., “Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid County-Regulator within the Immune System”, Critical Rev. Immunolgy, vol. 17, pp. 77-88 (1997).
Canduri, et al., “Structures of human purine nucleoside phosphorylase complexed with inosine and ddl”, Biochem. Biophys. Res. Comm., vol. 313, pp. 907-914 (2004).
Canduri, et al., “Crystal structure of human PNP complexed with hypoxanthine and sulfate ion”, Biochem. Biophys. Comm., vol. 326, pp. 335-338 (2005).
Chapman, John R., “Mass Spectrometry of Poteins and Peptides”, Methods in Molecular Biology, Humana Press, Totowa, New Jersey, vol. 146 (2000), Table of Contents.
Chaudhri, et al., “Mammalian and yeast 14-3-3 isoforms form patterns of dimmers in vivo”, Biochem. Biophys. Res. Comm., vol. 300, pp. 679-685 (2003).
Chen, et al., “Mammalian Polynucleotide Phosphorylase Is an Intermembrane Space RNase That Maintains Mitochondrial Homeostasis”, Molec. Cell. Biol., pp. 8475-8487 (2006).
Chen, et al., “Identification and characterization of PEBP as a calpain substrate”, J. Neurochem., vol. 99, pp. 1133-1141 (2006).
Corbit, et al., “Activation of Raf-1 Signaling by Protein Kinase C through a Mechanism Involving Raf Kinase Inhibitory Protein”, J. Biol. Chem., vol. 278(15), pp. 13061-13068 (2003).
Crouch, et al., “The use of ATP bioluminescence as a measure of cell proliferatin and cytotoxicity”, J. Immunol. Methods, vol. 160, pp. 81-88 (1993).
Donnelly, et al., “Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease”, Molec. Med. Today (Reviews), vol. 3, pp. 502-507 (1997).
Eddes, et al., “Chomper: A bioinformatics tool for rapid validation of tandem mass spectrometry search results associated with high-throughput proteomic strategies”, Proteomics, vol. 2, pp. 1097-1103 (2002).
Eng, et al., “An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database”, J. Am Soc. Mass Spectrum, vol. 5, pp. 976-989 (1994).
Evans, et al., “Pharmacogenomics: Translating Functional Genomics into Ratinal Therapeutics”, Science, vol. 286, pp. 487-491 (1999).
Fabre, et al., “Human hepatocytes as a key in vitro model to improve preclinical drug development”, Eur. J. Drug Metabolism Pharmacokinetics, vol. 15(2), pp. 165-171 (1990).
Fach, et al., “In Vitro Biomarker Discovery for Atherosclerosis by Proteomics”, Mol. Cell Proteomics, vol. 3, pp. 1200-1210 (2004).
Feo, S. et al. ENO1 gene product binds to the c-mycpromoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1(MBP-1), FEBS Letters, vol. 473, pp. 47-52 (2000).
Frank, R et al., “Clinical Biomarkers in Drug Discovery and Development”, Nature, vol. 2, pp. 566-580 (2003).
Fretland, A. et al., “Epoxide hydrolases: biochemistry and molecular biology”, Chemico-Biology Interactions, vol. 129, pp. 41-59 (2000).
Funk, C. et al., “Molecular cloning and amino acid sequence of leukotriene A4hydrolase”, PNAS, vol. 84, pp. 6677-6681 (1987).
Gao, J. et al., “Changes in the Protein Expression of Yeast as a Function of Carbon Source”, J. of Proteome Research, vol. 2, pp. 643-649 (2003).
Gao, J. et al., “Identification of in vitro protein biomarkers of idiosyncratic liver toxicity”, Toxicology in Vitro, vol. 18, pp. 533-541 (2004).
Gatlin, C. et al., “Automated Identification of Amino Acid Sequence Variations in Proteins by HPLC/Microspray Tandem Mass Spectrometry”, Anal. Chem., vol. 72, pp. 757-763 (2000).
Gerhard, D. et al., The Status, Quality, and Expansion of the NIH Full-Length cDNDA Project: The Mammalian Gene Collection (MGC), Genome Research, vol. 14, pp. 2121-2127 (2004).
Ghosh, A. et al., “A Novel 16-Kilodalton Cellular Protein Physically interacts with and Antagonizes the Functional Activity of c-mycPromoter-binding Protein 1”, Molecular and Cellular Biology, vol. 21(2), pp. 655-662 (2001).
Ghosh, A. et al., “Functional Domains of c-myc Promoter Binding Protein 1 Involved in Transcriptional Repression and Cell Growth Regulation”, Molecular & Cell. Biology, vol. 19(4), pp. 2880-2886 (1999).
Giallongo, A. et al., “Structure of the human gene for α-enolase”, Eur. J. Biochem., vol. 190, pp. 567-573 (1990).
Giallongo, A. et al., “Molecular cloning and nucleotide sequence of a full-length cDNA for human α enolase”, PNAS, vol. 83, pp. 6741-6745 (1986).
Green, A. J., “Cerebrospinal fluid brain-derived proteins in the diagno
Dambach Donna
Durham Stephen K.
Gao Ji
Garulacan Leah Ann
Hefta Stanley
Bristol--Myers Squibb Company
Cheu Jacob
D'Amico Stephen C.
Le Long V.
LandOfFree
Identification of biomarkers for liver toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of biomarkers for liver toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of biomarkers for liver toxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043792